Bedger,You must be an optimist.The recent annual report has...

Bedger,
You must be an optimist.
The recent annual report has (from memory) -Revenue about $1.5m, COGS - .5m (I assume that this is the cost of making the implants - a good gross profit margin), Sales and distribution - $1m, Administration - $4m("Administration" must be just a catch all for "all the other expenses"). So the revenue at this stage covers only the COGS and sales - an eon away from breakeven .
Can sales be markedly increased without increasing the payments to sales staff proportionally?
If Osteopore's implants become SOC, then , I agree, revenue will one day outstrip costs. How much competition there is is still somewhat unknown .

I should refrain from any more negative comments, lest I be accused of downramping. One great advantage that Osteopore has over other ASX biotechs is that it does not pay the researchers, and perhaps not for the studies (I will be asking that).